Problem.
Demonstrating efficacy is challenging with CNS therapeutics.
Only
8%
Phase 1 to FDA approval
Less than
½
as likely as other therapeutic areas
And
2x
as likely to fail in phase 3
CNS diseases are often complex, poorly defined, and difficult to measure. Also, patients are known to exhibit highly differential responses to CNS therapeutics, highlighting the need for patient measurement and stratification.
Solution.
Objective and automated measurement using multimodal AI enhances signal detection.

Increased
power.
Deliberate helps clinical trial sponsors achieve enhanced endpoint reliability, reduced sample size, faster completion, and lower cost.

Comprehensive measurement.
Our platform captures and analyzes signs beyond what a human clinician can perceive, including accurate side effect quantification.

Precision enrollment & enrichment.
With Deliberate, sponsors can screen and verify patients, capture validated baseline measures, and even perform patient enrichment via a companion Dx.
How we do it.
Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications

Distinguished Poster Award
18th Annual Scientific Meeting, 2022

Benefits for sponsors.
Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications

Make your CNS clinical trial
more Deliberate.

Measurement beyond human perception

Enhanced signal detection

Biomarker Constellation analysis and AI-COAs

Precision enrollment, enrichment, and companion Dx
